세계의 희귀 내분비 질환 치료 시장 보고서(2025년)

Rare endocrine disease treatment refers to the medical management of uncommon disorders that affect the hormone producing glands of the body. These treatments aim to restore hormonal balance, relieve symptoms, and prevent complications in order to improve patients' quality of life.

The primary types of rare endocrine disease treatment are biologics and organic compounds. Biologics are therapeutic products derived from living organisms or their components, such as proteins, cells, or nucleic acids, and are used to prevent, treat, or manage diseases. Treatment approaches include hormone replacement therapy, radiotherapy, surgery, targeted therapy, and immunotherapy, which are applied to conditions such as Cushing's syndrome, Addison's disease, acromegaly, and others. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, direct sales, and others, while end users encompass hospitals, specialty clinics, research institutes, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The rare endocrine disease treatment market research report is one of a series of new reports from The Business Research Company that provides rare endocrine disease treatment market statistics, including rare endocrine disease treatment industry global market size, regional shares, competitors with a rare endocrine disease treatment market share, detailed rare endocrine disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the rare endocrine disease treatment industry. This rare endocrine disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rare endocrine disease treatment market size has grown strongly in recent years. It will grow from $11.74 billion in 2024 to $12.58 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period was driven by increasing awareness of rare endocrine diseases, rising demand for hormone replacement therapies, growing prevalence of genetic and hormonal disorders, greater focus on specialized treatment centers, and expanding funding for rare disease research.

The rare endocrine disease treatment market size is expected to see strong growth in the next few years. It will grow to $16.41 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth during the forecast period is fueled by the development of biologics and targeted therapies, rising emphasis on patient centric care, increasing investments from pharmaceutical companies, growing demand for digital health and telemedicine in rare disease management, and expanding support programs from governments and non profit organizations. The primary trends in the forecast period include integration of artificial intelligence in diagnosis and treatment planning, advancement of telemedicine platforms for chronic disease care, innovation in biologic and peptide based therapies, progress in genetic and molecular research, and improvements in patient monitoring technologies.

The growing focus on precision medicine is expected to drive the expansion of the rare endocrine disease treatment market. Precision medicine tailors prevention, diagnosis, and treatment plans to an individual's genetic, environmental, and lifestyle factors. This approach is gaining traction due to advancements in genomics, which have improved the identification of disease mechanisms and facilitated the development of personalized treatment strategies. Precision medicine is especially beneficial in treating rare endocrine diseases by customizing therapies based on a patient's genetic, molecular, and hormonal profiles. This leads to more precise diagnoses and targeted treatments that increase effectiveness while minimizing side effects. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. These treatments included seven cancer drugs and three treatments for other conditions, highlighting the growing role of precision medicine in addressing rare diseases. As a result, the increasing focus on precision medicine is driving the growth of the rare endocrine disease treatment market.

Companies in the rare endocrine disease treatment market are focusing on advancing therapies such as parathyroid hormone (PTH) prodrugs to improve treatment efficacy and prolong therapeutic effects for patients. PTH prodrugs are hormone therapies that involve attaching polyethylene glycol (PEG) to PTH, enhancing stability, extending circulation time, and providing longer-lasting therapeutic benefits for endocrine disorders. For example, in August 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, received FDA approval for YORVIPATH, the first and only treatment for adult hypoparathyroidism, a rare endocrine disorder that affects around 70,000 to 90,000 people in the U.S. YORVIPATH uses Ascendis' TransCon prodrug technology to provide continuous PTH exposure, reduce dosing frequency, and normalize serum calcium levels. Phase 3 trial results showed that many patients achieved normal calcium levels without needing additional vitamin D or high doses of calcium, marking a significant improvement over standard therapies. This innovation enhances clinical outcomes and improves quality of life for adults with hypoparathyroidism by addressing both short- and long-term complications.

In July 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Amolyt Pharma SAS for $1.05 billion. The acquisition aims to strengthen AstraZeneca's late-stage rare disease pipeline and expand its bone metabolism franchise, particularly targeting rare endocrine conditions such as hypoparathyroidism. Amolyt Pharma SAS, based in France, is a clinical-stage biotechnology company focused on developing innovative therapies for rare endocrine diseases. This move positions AstraZeneca to address significant unmet needs in the rare endocrine disease treatment space.

Major players in the rare endocrine disease treatment market are Pfizer Inc., Bayer AG, AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Sandoz Group AG, Alexion Pharmaceuticals Inc., Ipsen S.A., Kyowa Kirin Co. Ltd., BioMarin Pharmaceutical Inc., Recordati S.p.A., Camurus AB, EMD Serono Inc., Corcept Therapeutics Inc., Ascendis Pharma A/S, Inozyme Pharma Inc., Spruce Biosciences Inc., MBX Biosciences Inc., Crinetics Pharmaceuticals Inc., Tiburio Therapeutics Inc.

North America was the largest region in the rare endocrine disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rare endocrine disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rare endocrine disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare endocrine disease treatment market consists of revenues earned by entities by providing services such as multidisciplinary clinical care, personalized treatment options, clinical trials and research care coordination, and long-term support. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare endocrine disease treatment market also includes sales of diagnostic imaging tools, laboratory and molecular diagnostic devices, monitoring & therapeutic devices, and Digital and Telemedicine Infrastructure. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Endocrine Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare endocrine disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rare endocrine disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rare endocrine disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Biologics; Organic Compounds
• 2) By Treatment: Hormone Replacement Therapy; Radiotherapy; Surgery; Targeted Therapy; Immunotherapy
• 3) By Disease: Cushing's Syndrome; Addison's Disease; Acromegaly; Other Diseases
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Direct Sales; Other Distribution Channels
• 5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
• Subsegments:
• 1) By Biologics: Monoclonal Antibodies; Recombinant Proteins; Enzyme Replacement Therapies; Vaccines
• 2) By Organic Compounds: Small Molecule Drugs; Peptide-Based Drugs; Steroidal Compounds; Non-Steroidal Compounds
• Companies Mentioned: Pfizer Inc.; Bayer AG; AstraZeneca PLC; Eli Lilly and Company; Novo Nordisk A/S; Sandoz Group AG; Alexion Pharmaceuticals Inc.; Ipsen S.A.; Kyowa Kirin Co. Ltd.; BioMarin Pharmaceutical Inc.; Recordati S.p.A.; Camurus AB; EMD Serono Inc.; Corcept Therapeutics Inc.; Ascendis Pharma A/S; Inozyme Pharma Inc.; Spruce Biosciences Inc.; MBX Biosciences Inc.; Crinetics Pharmaceuticals Inc.; Tiburio Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rare Endocrine Disease Treatment Market Characteristics

3. Rare Endocrine Disease Treatment Market Trends And Strategies

4. Rare Endocrine Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Rare Endocrine Disease Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Rare Endocrine Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Rare Endocrine Disease Treatment Market Growth Rate Analysis
• 5.4. Global Rare Endocrine Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Rare Endocrine Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Rare Endocrine Disease Treatment Total Addressable Market (TAM)

6. Rare Endocrine Disease Treatment Market Segmentation

• 6.1. Global Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics
• Organic Compounds
• 6.2. Global Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Replacement Therapy
• Radiotherapy
• Surgery
• Targeted Therapy
• Immunotherapy
• 6.3. Global Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cushing's Syndrome
• Addison's Disease
• Acromegaly
• Other Diseases
• 6.4. Global Rare Endocrine Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Direct Sales
• Other Distribution Channels
• 6.5. Global Rare Endocrine Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Research Institutes
• Other End-Users
• 6.6. Global Rare Endocrine Disease Treatment Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Recombinant Proteins
• Enzyme Replacement Therapies
• Vaccines
• 6.7. Global Rare Endocrine Disease Treatment Market, Sub-Segmentation Of Organic Compounds, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Drugs
• Peptide-Based Drugs
• Steroidal Compounds
• Non-Steroidal Compounds

7. Rare Endocrine Disease Treatment Market Regional And Country Analysis

• 7.1. Global Rare Endocrine Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Rare Endocrine Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rare Endocrine Disease Treatment Market

• 8.1. Asia-Pacific Rare Endocrine Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rare Endocrine Disease Treatment Market

• 9.1. China Rare Endocrine Disease Treatment Market Overview
• 9.2. China Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rare Endocrine Disease Treatment Market

• 10.1. India Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rare Endocrine Disease Treatment Market

• 11.1. Japan Rare Endocrine Disease Treatment Market Overview
• 11.2. Japan Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rare Endocrine Disease Treatment Market

• 12.1. Australia Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rare Endocrine Disease Treatment Market

• 13.1. Indonesia Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rare Endocrine Disease Treatment Market

• 14.1. South Korea Rare Endocrine Disease Treatment Market Overview
• 14.2. South Korea Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rare Endocrine Disease Treatment Market

• 15.1. Western Europe Rare Endocrine Disease Treatment Market Overview
• 15.2. Western Europe Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rare Endocrine Disease Treatment Market

• 16.1. UK Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rare Endocrine Disease Treatment Market

• 17.1. Germany Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rare Endocrine Disease Treatment Market

• 18.1. France Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rare Endocrine Disease Treatment Market

• 19.1. Italy Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rare Endocrine Disease Treatment Market

• 20.1. Spain Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rare Endocrine Disease Treatment Market

• 21.1. Eastern Europe Rare Endocrine Disease Treatment Market Overview
• 21.2. Eastern Europe Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rare Endocrine Disease Treatment Market

• 22.1. Russia Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rare Endocrine Disease Treatment Market

• 23.1. North America Rare Endocrine Disease Treatment Market Overview
• 23.2. North America Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rare Endocrine Disease Treatment Market

• 24.1. USA Rare Endocrine Disease Treatment Market Overview
• 24.2. USA Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rare Endocrine Disease Treatment Market

• 25.1. Canada Rare Endocrine Disease Treatment Market Overview
• 25.2. Canada Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rare Endocrine Disease Treatment Market

• 26.1. South America Rare Endocrine Disease Treatment Market Overview
• 26.2. South America Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rare Endocrine Disease Treatment Market

• 27.1. Brazil Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rare Endocrine Disease Treatment Market

• 28.1. Middle East Rare Endocrine Disease Treatment Market Overview
• 28.2. Middle East Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rare Endocrine Disease Treatment Market

• 29.1. Africa Rare Endocrine Disease Treatment Market Overview
• 29.2. Africa Rare Endocrine Disease Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Rare Endocrine Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Rare Endocrine Disease Treatment Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rare Endocrine Disease Treatment Market Competitive Landscape And Company Profiles

• 30.1. Rare Endocrine Disease Treatment Market Competitive Landscape
• 30.2. Rare Endocrine Disease Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

31. Rare Endocrine Disease Treatment Market Other Major And Innovative Companies

• 31.1. Sandoz Group AG
• 31.2. Alexion Pharmaceuticals Inc.
• 31.3. Ipsen S.A.
• 31.4. Kyowa Kirin Co. Ltd.
• 31.5. BioMarin Pharmaceutical Inc.
• 31.6. Recordati S.p.A.
• 31.7. Camurus AB
• 31.8. EMD Serono Inc.
• 31.9. Corcept Therapeutics Inc.
• 31.10. Ascendis Pharma A/S
• 31.11. Inozyme Pharma Inc.
• 31.12. Spruce Biosciences Inc.
• 31.13. MBX Biosciences Inc.
• 31.14. Crinetics Pharmaceuticals Inc.
• 31.15. Tiburio Therapeutics Inc.

32. Global Rare Endocrine Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rare Endocrine Disease Treatment Market

34. Recent Developments In The Rare Endocrine Disease Treatment Market

35. Rare Endocrine Disease Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Rare Endocrine Disease Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Rare Endocrine Disease Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Rare Endocrine Disease Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer